1. Home
  2. RPID vs GANX Comparison

RPID vs GANX Comparison

Compare RPID & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rapid Micro Biosystems Inc.

RPID

Rapid Micro Biosystems Inc.

SELL

Current Price

$0.78

Market Cap

84.8M

Sector

Health Care

ML Signal

SELL

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.16

Market Cap

76.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPID
GANX
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
84.8M
76.8M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
RPID
GANX
Price
$0.78
$1.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$5.75
★ $7.20
AVG Volume (30 Days)
199.4K
★ 647.2K
Earning Date
11-06-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
2.78
★ 31.46
EPS
N/A
★ N/A
Revenue
★ $33,587,000.00
$55,180.00
Revenue This Year
$16.95
N/A
Revenue Next Year
$17.92
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 19.74
N/A
52 Week Low
$0.76
$1.15
52 Week High
$4.94
$4.34

Technical Indicators

Market Signals
Indicator
RPID
GANX
Relative Strength Index (RSI) 26.99 26.05
Support Level $0.76 N/A
Resistance Level $2.18 $2.01
Average True Range (ATR) 0.06 0.11
MACD 0.01 -0.02
Stochastic Oscillator 8.53 2.78

Price Performance

Historical Comparison
RPID
GANX

About RPID Rapid Micro Biosystems Inc.

Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: